Cingulate Inc. is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. CTx-1301 and CTx-1302 utilize a flexible core tableting technology with target product profile designed to deliver a rapid onset and last the entire active day with a controlled descent of plasma drug level and have favorable tolerability. The Company has initiated Phase 3 clinical trials for CTx-1301, with first patients in the adult dose-optimization study dosed in early 2023. In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage.
Company profile
Ticker
CING
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Cingulate Therapeutics LLC • Cingulate Works Inc. ...
IRS number
863825535
CING stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
4 Apr 24
424B4
Prospectus supplement with pricing info
3 Apr 24
EFFECT
Notice of effectiveness
3 Apr 24
POS AM
Prospectus update (post-effective amendment)
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
1 Apr 24
8-K
Other Events
18 Mar 24
424B5
Prospectus supplement for primary offering
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Feb 24
8-K
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
13 Feb 24
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm | 1.99 mm |
Cash burn (monthly) | (no burn) | 650.77 k | 1.99 mm | 1.77 mm | 1.43 mm | 1.39 mm |
Cash used (since last report) | n/a | 4.34 mm | 13.29 mm | 11.78 mm | 9.54 mm | 9.27 mm |
Cash remaining | n/a | -2.35 mm | -11.30 mm | -9.79 mm | -7.55 mm | -7.28 mm |
Runway (months of cash) | n/a | -3.6 | -5.7 | -5.5 | -5.3 | -5.2 |
Institutional ownership, Q4 2023
7.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 20 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 3.59 mm |
Total shares | 365.71 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Peter J. Werth | 325.32 k | $3.20 mm |
Shane J. Schaffer | 40.39 k | $397.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Peter J. Werth | Common Stock | Option exercise | Acquire M | Yes | No | 0.0001 | 694,096 | 69.41 | 1,175,925 |
11 Apr 24 | Peter J. Werth | Common Stock | Option exercise | Acquire M | Yes | No | 0.002 | 341,912 | 683.82 | 481,829 |
11 Apr 24 | Peter J. Werth | Pre-Funded Warrant Common Stock | Option exercise | Dispose M | Yes | No | 0.0001 | 694,096 | 69.41 | 0 |
11 Apr 24 | Peter J. Werth | Pre-Funded Warrant Common Stock | Option exercise | Dispose M | Yes | No | 0.002 | 341,912 | 683.82 | 0 |
29 Mar 24 | Raul R. Silva | Stock Option Common Stock | Grant | Acquire A | No | No | 1.1 | 1,000 | 1.10 k | 1,000 |
29 Mar 24 | Matthew Brams | Stock Option Common Stock | Grant | Acquire A | No | No | 1.1 | 1,000 | 1.10 k | 1,000 |
25 Mar 24 | Peter J. Werth | Pre-Funded Warrant Common Stock | Other | Acquire J | Yes | No | 0.0001 | 7,053 | 0.71 | 694,096 |
4 Mar 24 | Shane J. Schaffer | Stock Option Common Stock | Grant | Acquire A | No | No | 1.18 | 57,323 | 67.64 k | 57,323 |
News
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 Feb 24
Peering Into Cingulate's Recent Short Interest
5 Feb 24
S&P 500 Gains Over 1%; Amazon Earnings Top Expectations
2 Feb 24
Why Skechers Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
2 Feb 24
12 Health Care Stocks Moving In Friday's Intraday Session
2 Feb 24
Press releases
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
16 Apr 24
Cingulate to Participate in Benzinga All Live Access Event
19 Mar 24
Cingulate to Attend DCAT Week 2024 in New York City
6 Mar 24
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
13 Feb 24
Cingulate Announces Closing of $7.5 Million Public Offering
6 Feb 24